Product Data Sheet

Product Name: HPG1860
Cat. No.: GC92033

Chemical Properties

Cas. No.	2226133-29-3		
Chemical Name	2-[(2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methyl]-2-methyl-1-piperazinyl]-4-methoxy-6-benzothiazolecarboxylic acid		
SMILES	COC1=C2C(SC(N3CCN(CC4=C(C5CC5)ON=C4C6=C(Cl)C=CC=C6Cl)C[C@H]3C)=N2)=CC(C(O)=O)=C1		
Formula	$C_{27}H_{26}Cl_2N_4O_4S$	M.Wt	573.5
Solubility	DMSO: Sparingly soluble: 1-10 mg/ml,Ethanol: Sparingly soluble: 1-10 mg/ml	Storage	-20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure			

Background

HPG1860 is a farnesoid X receptor (FXR) agonist.[1] It induces luminescence in a reporter assay using HEK293T cells expressing human FXR (EC_{50} = 18 nM). *In vivo*, HPG1860 (1, 3, or 10 mg/kg per day) decreases the serum levels of alanine transaminase (ALT) and total cholesterol, as well as hepatic inflammation, fat levels, and fibrosis, in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a high-fat diet and carbon tetrachloride (CCl_4).

References:

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

[1]. Mo, C., Xu, X., Zhang, P., et al.Discovery of HPG1860, a structurally novel nonbile acid FXR agonist currently in clinical development for the treatment of nonalcoholic steatohepatitisJ. Med. Chem.66(14)9363-9375(2023).